SCHEMBL733296

SCHEMBL733296

COc1ccc(-c2c[c]cc(OC)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
MAPT P10636 3/20 0.45
POLB P06746 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ENPP3 O14638 2/20 0.44
DYRK1A Q13627 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
ALOX5 P09917 1/20 0.43
GAA P10253 1/20 0.43
MCL1 Q07820 1/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732707 0.85 MEN1 (0.53) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL731454 0.81 DYRK1A (0.47) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL18255986 0.78 NPC1 (0.54) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL733118 0.73 DYRK3 (0.48) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL2132258 0.73 LMNA (0.39) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL3628069 0.72 NPC1 (0.61) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL730421 0.72 AKT2 (0.43) CLK4
SCHEMBL733059 0.72 NPC1 (0.40) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL5540994 0.71 CLK4 (0.52) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL29433131 0.71 LTB4R (0.62) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 NPC1 2438/4885RAB9A 2465/4885ALDH1A1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.